Francisco Chacón-Lozsán։ Why the Endothelial Glycocalyx Matters at the Bedside
Francisco Chacón-Lozsán, Fellow at World Extreme Medicine, Member of European Society of Intensive Care Medicine (ESICM) and American College of Cardiology, shared a post on LinkedIn about a recent article by Marcela de Almeida Lopes et al, published in Journal of Critical Care, adding:
”The endothelial glycocalyx: why it matters at the bedside
The endothelial glycocalyx is increasingly changing how we understand microcirculation, vascular permeability and fluid therapy in critically ill patients.
Rather than being simply a physical barrier covering the endothelium, the glycocalyx is a dynamic structure involved in mechanotransduction, vascular tone, anticoagulation and regulation of inflammatory cell adhesion.
This becomes particularly relevant during critical illness.
In sepsis, septic shock, trauma, burns, cardiac surgery and ARDS, inflammatory cytokines, oxidative stress, ischemia reperfusion, hyperglycemia and high catecholamine exposure can promote glycocalyx shedding. Importantly, excessive intravenous fluid administration may further contribute to this injury.
The consequence is not simply ‘capillary leak.’
Loss of glycocalyx integrity promotes interstitial edema, impaired oxygen diffusion, leukocyte and platelet adhesion, inflammation, microthrombosis and ultimately microcirculatory dysfunction.
One of the most clinically important concepts is its relationship with the revised Starling principle.
The effective oncotic pressure gradient is considered to exist primarily between plasma and the subglycocalyx space, rather than between plasma and the interstitium. Sustained venous end capillary reabsorption is minimal, with excess interstitial fluid predominantly returning through the lymphatic system.
This helps explain an everyday ICU observation:
Giving more fluid does not necessarily produce sustained intravascular volume expansion.
When the endothelial surface is already damaged, aggressive fluid administration may instead increase edema and potentially aggravate glycocalyx injury. This provides a physiological rationale for increasingly individualized and restrictive fluid strategies rather than indiscriminate liberal resuscitation.
Can we monitor the glycocalyx?
Syndecan 1, heparan sulfate, glycosaminoglycans and hyaluronan have been studied as circulating markers of shedding. Handheld vital microscopy can evaluate the microcirculation and estimate parameters associated with glycocalyx integrity, but these remain indirect measurements and are not yet standardized for routine clinical practice.
For now, perhaps the most clinically applicable strategy is prevention: avoid unnecessary fluid overload, control hyperglycemia, treat sepsis effectively and minimize ischemia reperfusion injury. No therapy has yet been conclusively demonstrated to regenerate the human glycocalyx.”
Title: What every intensivist should know about the endothelial glycocalyx
Authors: Marcela de Almeida Lopes, Dimitri Gusmao-Flores, Can Ince
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 19, 2026, 08:39Choosing the Right P2Y12 Inhibitor After PCI – JAMA Cardiology
-
Aug 19, 2026, 08:05Charles Cohen: Why Women Wait Years Longer for a Bleeding Disorder Diagnosis
-
Aug 19, 2026, 07:42Chukwuemeka Amarachi: Thalassemia – Types, Diagnosis and Management
-
Aug 19, 2026, 07:15Ajay Kumar: Real-World Outcomes of Plasma Exchange in NMOSD
-
Aug 19, 2026, 07:02Amer Zeidan: Managing Anemia in Lower-Risk MDS
-
Aug 19, 2026, 06:24GT Connect – Connecting the GT Community – Glanzmann’s Research Foundation
-
Aug 19, 2026, 01:43Elvira Grandone: Cancer and Thrombosis in Women – Where Do We Stand?
-
Aug 19, 2026, 01:37Ifeanyichukwu Ifechidere: Coagulation Knowledge – A Core Skill in Internal Medicine
-
Aug 19, 2026, 01:34Tommy Alfaro Moya: Celebrating a New Chapter Contribution in Clinical Hematology and Hemato-Oncology